alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>



<ARTICLE> 5
<LEGEND>
THE SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AS OF SEPTEMBER 30, 1998 AND FROM THE STATEMENT OF OPERATIONS FOR THE NINE
MONTHS ENDED SEPTEMBER 30, 1998 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                         578,783
<SECURITIES>                                         0
<RECEIVABLES>                                    1,593
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0<F1>
<PP&E>                                      10,106,119
<DEPRECIATION>                                       0<F2>
<TOTAL-ASSETS>                              10,823,588
<CURRENT-LIABILITIES>                                0<F1>
<BONDS>                                      5,143,957
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   5,481,636
<TOTAL-LIABILITY-AND-EQUITY>                10,823,588
<SALES>                                      1,450,721
<TOTAL-REVENUES>                             1,471,264
<CGS>                                                0
<TOTAL-COSTS>                                1,173,121
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             297,781
<INCOME-PRETAX>                                    362
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                362
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       362
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
<FN>
<F1>THE PARTNERSHIP HAS AN UNCLASSIFIED BALANCE SHEET, THEREFORE THE VALUE IS $0.
<F2>THIS INFORMATION IS NOT DISCLOSED IN THE PARTNERSHIP'S FORM 10-Q FILING.
</FN>
        

</TABLE>
# C_2015213EN.01004101.xml

| 29.6.2015 | EN | Official Journal of the European Union | C 213/41 |
| --- | --- | --- | --- |

29.6.2015

EN

Official Journal of the European Union

C 213/41

---

Order of the General Court of 4 May 2015 — Spain v Commission

(Case T-25/14) (1)

1

(2015/C 213/67)

Language of the case: Spanish

The President of the First Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 61, 1.3.2014.

1

---
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5995 Tee drain (water trap). ( a ) *Identification.* A tee drain (water trap) is a device intended to trap and drain water that collects in ventilator tubing during respiratory therapy, thereby preventing an increase in breathing resistance.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 61 FR 1120, Jan. 16, 1996; 66 FR 38796, July 25, 2001]
1845 - 0039

– Affected Public

– Not - for- Profit Institutions 3 / 17 /201 5

Institutions are required to report student Pell Grant pay ment information to ED electronicall y. Electronic reporting is conducted through the Common Origination and Disbursement (COD) system. The COD s ys tem is used by institutions to request, report, and reconcile grant funds received from the Pell Grant program. ED uses the information collected in the COD s ys tem to aid in ensuring compliance with fiscal and administrative requirements under the HEA for the Pell Grant program and under 34 CFR 690 for the Pell Grant program regulations. The minimum reporting requirement is one record for origination and disbursement data per student, per grant award, per award ye ar. Institutions may correct an accepted COD record as many times as they

wish, but are n ot required to submit changes unless the student’s award amount changes from the accepted origination amount originall y established in COD. For the 2014 - 2015 award year, the projected number of FAFSA completers is expected to be reduced b y 2.86%. Based o n the 8,738,722 unduplicated student recipients for the Federal Pell Grant program for 2013 - 2014, the number of unduplicated Federal Pell Grant recipients for 2014 - 2015 is estimated to be 8,488,843 multiplied by .07 hours per recipient for all institution s to enter data in the COD sy stem for a total of 594,219 burden hours. 1 , 717 Not - f

or- Profit institutions 1, 103 , 549 responses X .07 hours = 77 , 248 burden hours
§ 186.1557 Tall oil. ( a ) Tall oil (CAS Reg. No. 8002-26-4) is essentially the sap of the pine tree. It is obtained commercially from the waste liquors of pinewood pulp mills and consists mainly of tall oil resin acids and tall oil fatty acids.
( b ) In accordance with § 186.1(b)(1), the ingredient is used as an indirect human food ingredient with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as an indirect human food ingredient is based on the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a constituent of cotton and cotton fabrics used for dry food packaging.
( 2 ) The ingredient is used at levels not to exceed current good manufacturing practice.
( c ) Prior sanctions for this ingredient different from the uses established in this section, or from those listed in part 181 of this chapter, do not exist or have been waived.
[51 FR 16830, May 7, 1986]
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Third Meeting on the Conduct of Monetary Policy

              																	United States. Congress. Senate. Committee on Banking, Housing, and Urban Affairs, 1970-					 and 	Ninety-Fourth Congress, 1975-1977. 						*Third Meeting on the Conduct of Monetary Policy : Hearings Before the Committee on Banking, Housing, and Urban Affairs, United States Senate, Ninety-fourth Congress, Second Session, May 3, 4, and 5, 1976*,												Washington: 								U.S. Government Printing Office, 										May 3, 4, and 5, 1976,									https://fraser.stlouisfed.org/title/1089,			accessed on September 22, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
U.S. GOVERNMENT PUBLISHING OFFICE

WASHINGTON : 

1 

89–011 2019

116th Congress, 1st Session – – – – – – – – – – – – – House Document 116–32 

DESIGNATING BRAZIL AS A MAJOR NON-NATO ALLY 

MESSAGE 

FROM

THE PRESIDENT OF THE UNITED STATES 

TRANSMITTING

NOTICE OF THE INTENT TO DESIGNATE BRAZIL AS A MAJOR 

NON-NATO ALLY, PURSUANT TO 22 U.S.C. 2321k(a); PUBLIC LAW 

87–195, SEC. 517 (AS ADDED BY PUBLIC LAW 104–164, TITLE I, 

SEC. 147(a)(1)); (110 STAT. 1434) 

MAY 8, 2019.—Message and accompanying papers referred to the 

Committee on Foreign Affairs and ordered to be printed 


SSpencer on DSKBBXCHB2PROD with REPORTSE:\Seals\Congress.#13

SSpencer on DSKBBXCHB2PROD with REPORTS
(1) 

To the Congress of the United States: 

In accordance with section 517 of the Foreign Assistance Act of 

1961, as amended (22 U.S.C. 2321k), I am providing notice of my 

intent to designate Brazil as a Major Non-NATO Ally. 

I am making this designation in recognition of the Government 

of Brazil’s recent commitments to increase defense cooperation with 

the United States, and in recognition of our own national interest 

in deepening our defense coordination with Brazil. 

DONALD J. TRUMP. 

THE WHITE HOUSE, May 8, 2019. 

Æ 


SSpencer on DSKBBXCHB2PROD with REPORTS
§ 522.2444a Thiopental powder for injection. ( a ) *Specifications.* The drug contains sodium thiopental powder for constitution with sterile water for injection.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* Administer by intravenous injection as follows: ( i ) 6 to 9 milligrams (mg) per pound of body weight for brief anesthesia (6 to 10 minutes).
( ii ) 10 to 12 mg per pound of body weight for anesthesia of 15 to 25 minutes duration.
( 2 ) *Indications for use.* It is used as an anesthetic for intravenous administration to dogs and cats during short to moderately long surgical and other procedures. It is also used to induce anesthesia in dogs and cats which then have surgical anesthesia maintained by use of a volatile anesthetic.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16196, Mar. 25, 2014]
Exhibit 23.1CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMWe hereby consent to the incorporation by reference in the Registration Statements on Form S-8(333-53374, 333-105963 and 333-127025) and Form S-3 (333-106126, 333-117264, 333-119864,333-128074, 333-138748, 333-143023 and 333-149030) of Evergreen Solar, Inc. of our report datedFebruary 27, 2008 relating to the financial statements, financial statement schedule and theeffectiveness of internal control over financial reporting, which appears in this Form 10-K./s/ PricewaterhouseCoopers LLP
Exhibit 32.1

# Written Statement of
the Chief Executive Officer and Chief Financial OfficerPursuant to 18 U.S.C.
§1350

Solely
for the purposes of complying with 18 U.S.C. §1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, we, the undersigned President and Chief Executive
Officer and Vice President Law/Finance and Secretary of Ladish Co., Inc. (the
Company), hereby certify, based on our knowledge, that the Quarterly Report on
Form 10-Q of the Company for the quarter ended March 31, 2005 (the Report)
fully complies with the requirements of Section 13(a) of the Securities Exchange Act of
1934 and that information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

|                                                       | 
|------------------------------------------------------ | 
|/s/  Kerry L. Woody                                    | 
|Kerry L. Woody
President and Chief Executive Officer   | 
|/s/  Wayne E. Larsen                                   | 
|Wayne E. Larsen
Vice President Law/Finance & Secretary | 

April 21, 2005
**Exhibit 31.2****CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER****PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**I, Timothy P. O’Neil, certify that:1. I have reviewed this annual report on Form 10-K of LOUD Technologies Inc.;2. Based on my knowledge, this report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, not misleading withrespect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respects thefinancial condition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this report;4. The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined in ExchangeAct Rules 13a-15(e) and 15d-15(e)) for the registrant and have:     (a)Designed such disclosure controls and procedures, or causedsuch disclosure controls and procedures to be designed under oursupervision, to ensure that material information relating to the registrant,including its consolidated subsidiaries, is made known to us by otherswithin those entities, particularly during the period in which this reportis being prepared;     (b) Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by this reportbased on such evaluation; and     (c) Disclosed in this report any change in the registrant’s internal control overfinancial reporting that occurred during the registrant’s most recent fiscal quarterthat has materially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors andthe audit committee of the registrant’s board of directors:     (a) All significant deficiencies and material weaknesses in the design oroperation of internal control over financial reporting which are reasonably likely toadversely affect the registrant’s ability to record, process, summarize and reportfinancial information; and     (b) Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the registrant’s internal control overfinancial reporting.       Dated: April 16, 2007 By: /s/ Timothy P. O’Neil Timothy P. O’Neil      *Chief Financial Officer, Senior Vice President,*      *Secretary and Treasurer*
Editorial Note on Part 860
Editorial Note: Nomenclature changes to part 860 appear at 73 FR 35341, June 23, 2008, and at 86 FR 54846, Oct. 5, 2021.

§ 860.250 Withdrawal of a De Novo request. ( a ) FDA considers a De Novo request to have been withdrawn if: ( 1 ) The requester fails to provide a complete response to a request for additional information pursuant to § 860.240(b)(1) within 180 days after the date FDA issues such request;
( 2 ) The requester fails to provide a complete response to the deficiencies identified by FDA pursuant to § 860.230(c)(2) within 180 days of the date notification was issued by FDA;
( 3 ) The requester does not permit an authorized FDA employee an opportunity to inspect the facilities, pursuant to § 860.240(c), at a reasonable time and in a reasonable manner, and to have access to copy and verify all records pertinent to the De Novo request; or
( 4 ) The requester submits a written notice to FDA that the De Novo request has been withdrawn.
( b ) If a De Novo request is withdrawn, the Agency will notify the requester. The notice will include the De Novo request reference number and the date FDA considered the De Novo request withdrawn.
---

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350AS
ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Smart-tek Solutions,
Inc., (the "Company") on Form 10KT/A Amendment N0. 1 for the six month period
ending December 31, 2010 as filed with the Securities and Exchange Commission on
the date hereof (the "Report"), I, Brian Bonar, Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec.
906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigneds
knowledge and belief:

(1) The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934; and

(2) The information contained in
the Report fairly presents, in all material respects, the financial condition
and result of operations of the Company.

/s/ Brian BonarBrian BonarChief Executive
Officer, President and Director

August 1, 2011

---
(logo) pwc

 

 

**Report of Independent RegisteredPublic Accounting Firm**

 

To the Board of Directors, PNCFinancial Services Group, Inc.:

 

We have examinedmanagement’s assertion, included in the accompanying Report on Assessmentof Compliance with Regulation AB Servicing Criteria, that Midland LoanServices, a division of PNC Bank, National Association (“Midland”or the “Company”) complied with the servicing criteria set forth inItem 1122(d) of the Securities and Exchange Commission's Regulation AB for alltransactions serviced on the *Enterprise!* Loan Management System (the“Platform”), as of December 31, 2016 and for the year then ended,excluding criteria 1122(d)(1)(iii), 1122(d)(3)(i)(B), 1122(d)(3)(i)(C),1122(d)(3)(i)(D), 1122(d)(3)(ii), 1122(d)(3)(iii), 1122(d)(3)(iv), and 1122(d)(4)(xv),which the Company has determined are not applicable to the servicing activitiesperformed by it with respect to the Platform. Management is responsible for theCompany's compliance with the servicing criteria. Our responsibility is toexpress an opinion on management's assertion based on our examination.

 

Our examination was conductedin accordance with attestation standards of the Public Company AccountingOversight Board (United States) and, accordingly, included examining, on a testbasis, evidence about the Company’s compliance with the applicableservicing criteria and performing such other procedures as we considerednecessary in the circumstances. Our examination included testing of selectedasset-backed transactions and securities that comprise the Platform, testing ofselected servicing activities related to the Platform, and determining whetherthe Company processed those selected transactions and performed those selectedactivities in compliance with the applicable servicing criteria. Our procedureswere limited to the selected transactions and servicing activities performed bythe Company during the period covered by this report. Our procedures were notdesigned to detect noncompliance arising from errors that may have occurredprior to or subsequent to our tests that may have affected the balances oramounts calculated or reported by the Company during the period covered by thisreport. We believe that our examination provides a reasonable basis for ouropinion. Our examination does not provide a legal determination on theCompany’s compliance with the servicing criteria.

 

In our opinion,management’s assertion that Midland complied with the aforementionedapplicable servicing criteria as of and for the year ended December 31, 2016for the Platform is fairly stated, in all material respects.

 

 

/s/ PricewaterhouseCoopers LLP

 

February 17, 2017

 

 

*PricewaterhouseCoopers LLP,1100 Walnut Street, Suite 1300, Kansas City, MO 64106*

*T: (816) 472 7921, F: (816)218 1890 www.pwc.com/us*

* *
#### § 601.15 Foreign establishments and products: samples for each importation.

Random samples of each importation, obtained by the District Director of Customs and forwarded to the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research (see mailing addresses in § 600.2(c) of this chapter) must be at least two final containers of each lot of product. A copy of the associated documents which describe and identify the shipment must accompany the shipment for forwarding with the samples to the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research (see mailing addresses in § 600.2(c)). For shipments of 20 or less final containers, samples need not be forwarded, provided a copy of an official release from the Center for Biologics Evaluation and Research or Center for Drug Evaluation and Research accompanies each shipment.

[70 FR 14983, Mar. 24, 2005, as amended at 80 FR 18092, Apr. 3, 2015]
<TABLE> <S> <C>

<PAGE>


<ARTICLE> 5
<LEGEND>
THE SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AS OF JUNE 30, 1997 AND FROM THE STATEMENT OF OPERATIONS FOR THE SIX
MONTHS ENDED JUNE 30, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               JUN-30-1997
<CASH>                                         521,495
<SECURITIES>                                         0
<RECEIVABLES>                                    2,707
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0<F1>
<PP&E>                                      10,630,602
<DEPRECIATION>                                       0<F2>
<TOTAL-ASSETS>                              11,299,250
<CURRENT-LIABILITIES>                                0<F1>
<BONDS>                                      5,277,668
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   5,788,892
<TOTAL-LIABILITY-AND-EQUITY>                11,299,250
<SALES>                                        986,773
<TOTAL-REVENUES>                               996,200
<CGS>                                                0
<TOTAL-COSTS>                                  703,366
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             223,373
<INCOME-PRETAX>                                  (319)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              (319)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (319)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
<FN>
<F1>THE PARTNERSHIP HAS AN UNCLASSIFIED BALANCE SHEET; THEREFORE, THE VALUE IS $0.
<F2>THIS INFORMATION IS NOT DISCLOSED IN THE PARTNERSHIP'S FORM 10-Q FILING.
</FN>
        

</TABLE>